Mazzarella, 2011 - Google Patents
CMYC PROMOTER BINDINGPROTEIN 1 (MBP1) AS A NOVEL MARKER TO IDENTIFY NEW SUBTYPES OF ERBB2 NEGATIVE BREAST TUMORSMazzarella, 2011
View PDF- Document ID
- 7096056785017955185
- Author
- Mazzarella C
- Publication year
External Links
Snippet
RESULTS AND DISCUSSION 32 Preliminary results 33 MBP-1 regulates ERBB2 expression in SKBR3 breast cancer cells 35 Exogenous MBP-1 regulates ERBB2 promoter 38 Reporter Vector costruction 38 Reporter essays 40 MBP-1 binds ERBB2 promoter in vivo …
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Christopoulos et al. | The role of the insulin-like growth factor-1 system in breast cancer | |
Revillion et al. | ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis | |
Xu et al. | S100A14, a member of the EF-hand calcium-binding proteins, is overexpressed in breast cancer and acts as a modulator of HER2 signaling | |
JP2022125079A (en) | Methods for prognosis and treatment of cancer metastasis | |
JP6550045B2 (en) | Methods for prognosis and treatment of breast cancer-derived bone metastasis cancer | |
Tobin et al. | The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer | |
US20230366035A1 (en) | Biomarker for her2-positive cancer and anti-her2 therapy and applications thereof | |
Pradip et al. | Dissecting GRB7-mediated signals for proliferation and migration in HER2 overexpressing breast tumor cells: GTP-ase rules | |
KR20150122731A (en) | Method for the prognosis and treatment of cancer metastasis | |
Montemurro et al. | Biomarkers of drugs targeting HER‐family signalling in cancer | |
KR20150028965A (en) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis | |
WO2008144345A2 (en) | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators | |
EP2890815A2 (en) | Methods for diagnosis and treatment of cancer | |
EP2997181A1 (en) | Methods of prognostically classifying and treating glandular cancers | |
KR20110018930A (en) | Identification and use of prognostic and predictive markers in cancer treatment | |
KR20190140952A (en) | ERBB2 / HER2 mutations in transmembrane and proximal membrane domains | |
EP2633070A1 (en) | New marker of breast tumors from the luminal-b sybtype | |
KR102338510B1 (en) | Companion diagnostic biomarker for anti-her2 therapy and use thereof | |
Bertozzi et al. | Biomarkers in breast cancer | |
US20100297624A1 (en) | Involvement of Lipid Kinase, and Signal Transduction Pathway Comprising Said Lipid Kinase, in Resistance to HER2-Targeting Therapy | |
Christodoulou et al. | Evaluation of the insulin-like growth factor receptor pathway in patients with advanced breast cancer treated with trastuzumab | |
US10190170B2 (en) | Maker for diagnosing HER2 inhibitor resistant cancer, diagnostic kit comprising same, and method for diagnosing HER2 inhibitor resistant cancer | |
KR101875935B1 (en) | A Biomarker of the resistance about HER2 inhibitor | |
JP6858563B2 (en) | Prediction of EGFR inhibitor effect by BRAF mutation detection | |
Mazzarella | CMYC PROMOTER BINDINGPROTEIN 1 (MBP1) AS A NOVEL MARKER TO IDENTIFY NEW SUBTYPES OF ERBB2 NEGATIVE BREAST TUMORS |